oxybutynin has been researched along with Adverse Drug Event in 13 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 9.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 5.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| "Short-term treatment using oral extended-release oxybutynin 5 mg once daily was safe and well tolerated, with no delirium, in older female nursing home participants with mild to severe dementia." | 5.13 | Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. ( Davey, C; Lackner, TE; McCarthy, TC; Monigold, M; Wyman, JF, 2008) |
| "The first-line drug treatment for lower urinary tract symptoms, orally administered antimuscarinics, fails to reach the equilibrium dissociation constant of muscarinic receptors even at their maximum plasma concentration and tends to evoke a half-maximal response at a muscarinic receptor occupancy of just 0." | 3.01 | Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options. ( Beckel, J; Chancellor, M; Chermansky, C; Cho, KJ; Ganguly, A; Hashimoto, M; Kanai, A; Kaufman, J; Tyagi, P; Tyagi, S; Yoshimura, N, 2023) |
| "Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23." | 2.72 | Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. ( Anderson, RU; Barada, JH; Goldberg, RP; Kell, S; MacDiarmid, S; Serels, S, 2006) |
| "Oxybutynin 15 mg was more effective than propiverine 20 mg in reducing symptomatic and asymptomatic IDCs in ambulatory patients." | 2.72 | Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. ( Abrams, P; Cardozo, L; Chapple, C; Hargreaves, K; Khullar, V; Serdarevic, D, 2006) |
| " However, medication administration errors abound with this dosage form and frequently result in harm or treatment failure." | 2.50 | A systematic review of medication administration errors with transdermal patches. ( Haefeli, WE; Lampert, A; Seiberth, J; Seidling, HM, 2014) |
| " In addition to recommendations on the site and duration of TDDS application and proper patch disposal, clinicians must consider (1) potential problems with cutting patches as a method of dosage adjustment, (2) safety concerns related to the electric conductivity of metal-containing patches, (3) appropriate strategies for managing patch adhesion failures, and (4) the advisability of writing on patches for medication safety or compliance reasons." | 2.48 | Practical considerations for optimal transdermal drug delivery. ( Alhammad, A; Durand, C; Willett, KC, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Ganguly, A | 1 |
| Tyagi, S | 1 |
| Chermansky, C | 1 |
| Kanai, A | 1 |
| Beckel, J | 1 |
| Hashimoto, M | 1 |
| Cho, KJ | 1 |
| Chancellor, M | 1 |
| Kaufman, J | 1 |
| Yoshimura, N | 1 |
| Tyagi, P | 1 |
| Johnson, MH | 1 |
| Nepple, KG | 1 |
| Peck, V | 1 |
| Trinkaus, K | 1 |
| Klim, A | 1 |
| Sandhu, GS | 1 |
| Kibel, AS | 1 |
| Anderson, RU | 1 |
| MacDiarmid, S | 1 |
| Kell, S | 1 |
| Barada, JH | 1 |
| Serels, S | 1 |
| Goldberg, RP | 1 |
| Abrams, P | 1 |
| Cardozo, L | 1 |
| Chapple, C | 1 |
| Serdarevic, D | 1 |
| Hargreaves, K | 1 |
| Khullar, V | 1 |
| Lackner, TE | 1 |
| Wyman, JF | 1 |
| McCarthy, TC | 1 |
| Monigold, M | 1 |
| Davey, C | 1 |
| Lampert, A | 1 |
| Seiberth, J | 1 |
| Haefeli, WE | 1 |
| Seidling, HM | 1 |
| Aschenbrenner, DS | 1 |
| Webster, LR | 1 |
| Peppin, JF | 1 |
| Murphy, FT | 1 |
| Lu, B | 1 |
| Tobias, JK | 1 |
| Vanhove, GF | 1 |
| Durand, C | 1 |
| Alhammad, A | 1 |
| Willett, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population[NCT02385500] | Phase 4 | 5 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Insufficient or untimely patient recruitment) | ||
| A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain[NCT00082316] | Phase 2 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for oxybutynin and Adverse Drug Event
| Article | Year |
|---|---|
Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.
Topics: Administration, Intravesical; Aged; Botulinum Toxins, Type A; Drug-Related Side Effects and Adverse | 2023 |
A systematic review of medication administration errors with transdermal patches.
Topics: Administration, Cutaneous; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; H | 2014 |
Practical considerations for optimal transdermal drug delivery.
Topics: Administration, Cutaneous; Drug Delivery Systems; Drug Industry; Drug-Related Side Effects and Adver | 2012 |
5 trials available for oxybutynin and Adverse Drug Event
| Article | Year |
|---|---|
Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cel | 2013 |
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Demography; Drug-Related Side Effects and Adverse Reacti | 2006 |
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Topics: Benzilates; Cross-Over Studies; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions | 2006 |
Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.
Topics: Accidental Falls; Administration, Oral; Aged; Aged, 80 and over; Cognition; Confusion; Delayed-Actio | 2008 |
Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Topics: Aged; Anesthetics, Local; Capsaicin; Diabetic Neuropathies; Drug-Related Side Effects and Adverse Re | 2011 |
5 other studies available for oxybutynin and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Sumatriptan Patch is Temporarily Suspended.
Topics: Administration, Cutaneous; Burns; Drug-Related Side Effects and Adverse Reactions; Humans; Migraine | 2016 |